Outlook Therapeutics (NASDAQ: OTLK) is one of 122 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Outlook Therapeutics to related companies based on the strength of its earnings, dividends, institutional ownership, valuation, profitability, risk and analyst recommendations.
Insider & Institutional Ownership
0.8% of Outlook Therapeutics shares are held by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 11.5% of Outlook Therapeutics shares are held by insiders. Comparatively, 16.9% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of recent ratings for Outlook Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Outlook Therapeutics Competitors||905||2941||6324||280||2.57|
Outlook Therapeutics presently has a consensus price target of $9.33, indicating a potential upside of 407.25%. As a group, “Biological products, except diagnostic” companies have a potential upside of 45.55%. Given Outlook Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Outlook Therapeutics is more favorable than its rivals.
This table compares Outlook Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Outlook Therapeutics Competitors||-4,670.94%||-78.62%||-34.79%|
Risk and Volatility
Outlook Therapeutics has a beta of -0.81, suggesting that its stock price is 181% less volatile than the S&P 500. Comparatively, Outlook Therapeutics’ rivals have a beta of 1.77, suggesting that their average stock price is 77% more volatile than the S&P 500.
Earnings and Valuation
This table compares Outlook Therapeutics and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Outlook Therapeutics||$3.09 million||-$30.09 million||-0.17|
|Outlook Therapeutics Competitors||$853.15 million||$178.74 million||-0.33|
Outlook Therapeutics’ rivals have higher revenue and earnings than Outlook Therapeutics. Outlook Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Outlook Therapeutics rivals beat Outlook Therapeutics on 7 of the 13 factors compared.
About Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.